About WANECAM 2

WANECAM 2

WANECAM is the West African Network for Clinical Trials of Antimalarial drugs. This network is being supported by grants from the European & Developing Countries Clinical Trials Partnership (EDCTP).
The WANECAM 2 project aims to accelerate the development of the Ganaplacide/lumefantrine combination for the treatment of uncomplicated malaria by conducting clinical trials in four countries in West and Central Africa: Burkina Faso, Gabon, Mali and Niger. Moreover, and very importantly, the project includes activities around capacity building (e.g. training and infrastructure development) to improve the capabilities in West African countries to develop new antimalarial drugs. The aim is to advance the development of a much-needed new antimalarial therapy while strengthening clinical trial development capabilities in Africa.

06.2006 Burkina Faso, Anna Wang — The **WANECAM 2** project includes participants from West Africa and Europe and is coordinated by Prof Djimde from the University of Bamako. See a full list of our collaborators).

Our governance

A world without malaria.

Clinical development of a new combination of anti-malarial therapy, Ganaplacide/Lumefantrine for malaria control and elimination.

The objectives of WANECAM 2 are:

To accelerate the clinical development and, if successful, registration of this new innovative anti-malarial drug candidate Ganaplacide combined with a new formulation of lumefantrine (solid dispersion formulation, LUM-SDF) and evaluate its safety, tolerability and efficacy in the treatment of uncomplicated falciparum malaria in children aged 6 months and above, and adults in West and Central Africa;

To further develop capacities in clinical research, laboratory skills and infrastructure in sub-Saharan Africa by significantly enhancing the clinical trial expertise of a new clinical research team in Niger, improving targeted capacities and other infrastructure in all teams involved as well as training young African and European scientists;

To strengthen and expand the existing previously EDCTP funded West African network for clinical trials of antimalarial drugs (WANECAM 2) through intra-European, European-African and intra-African collaborative activities.